Literature DB >> 18725544

Contribution of down-regulation of intestinal and hepatic cytochrome P450 3A to increased absorption of cyclosporine A in a rat nephrosis model.

Tomoe Fujita1, Shuichi Yasuda, Yuji Kamata, Kazumi Fujita, Yoshio Ohtani, Yuji Kumagai, Masataka Majima.   

Abstract

This study examined the contribution of changes in regulation of intestinal and hepatic cytochrome P450 3A (CYP3A) and multidrug resistance transporter 1 (Mdr1) to absorption of cyclosporine A (CsA) in a rat nephrosis model. Interleukin (IL)-6 was also measured. Puromycin aminonucleoside at a dose of 20 mg/100 g was administered intravenously. Tissue samples were dissected out from the upper and middle intestines and liver after development of nephrosis to measure the expression levels of mRNA and protein. CsA at a dose of 0.5 mg/100 g was administered into a closed loop of the upper and middle intestines. Blood from the inferior vena cava (IVC) and portal vein was taken until 30 min after administration. The expression levels of CYP3A decreased markedly, whereas those of Mdr1 showed large interindividual variations for all of the tissues in the nephrotic rats. Plasma concentrations of CsA reached higher levels in the nephrotic than in the control rats and were higher when administered from the upper than the middle intestine in both the portal vein and IVC. IL-6 increased in urine in the nephrotic rats. In summary, intestinal and hepatic CYP3A were down-regulated in the nephrosis model accompanying the increased levels of IL-6. Consistent results were not obtained for the regulation of Mdr1. In conclusion, these findings suggest that the down-regulation of CYP3A in the upper intestine and liver predominantly contributes to the increase in CsA absorption, and Mdr1 showed less contribution in this rat nephrosis model.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18725544     DOI: 10.1124/jpet.108.142091

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  4 in total

1.  Combination therapy with diltiazem plus CsA/MMF/Pred or CsA/Aza/Pred triple immunosuppressive regimens for use in clinical kidney transplantation in Northwestern China.

Authors:  Yong Song; Wujun Xue; Puxun Tian; Xiaoming Ding; Xiaoming Pan; Hang Yan; Jun Hou; Xinshun Feng; Heli Xiang; Xiaohui Tian; Gaoping Qin; Xiaohu Fan
Journal:  Eur J Clin Pharmacol       Date:  2011-01-29       Impact factor: 2.953

2.  A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer.

Authors:  Gary Hudes; Scott T Tagawa; Young E Whang; Ming Qi; Xiang Qin; Thomas A Puchalski; Manjula Reddy; Mark Cornfeld; Mario Eisenberger
Journal:  Invest New Drugs       Date:  2012-07-25       Impact factor: 3.850

3.  Inhibitive effect of cremophor RH40 or tween 80-based self-microemulsiflying drug delivery system on cytochrome P450 3A enzymes in murine hepatocytes.

Authors:  Zichao Rao; Luqin Si; Yanbin Guan; Hongping Pan; Jun Qiu; Gao Li
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-11-10

Review 4.  Pharmaceutical Excipients and Drug Metabolism: A Mini-Review.

Authors:  Rahul Patel; James Barker; Amr ElShaer
Journal:  Int J Mol Sci       Date:  2020-11-03       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.